BioInformant

Your Global Leader in Stem Cell Market Research

Home » cynata » Page 2

U.S. Patent Granted for Cynata Cymerus™ Technology

By Leave a Comment

Melbourne, Australia; 27 September 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering aspects of Cynata’s proprietary Cymerus™ mesenchymal stem cell technology.

Cymerus PatentThe patent entitled “A method of making primate cells expressing apelin receptor that have mesangioblast potential” covers certain proprietary methods relating to the platform’s ability to efficiently manufacture mesenchymal stem cells at scale. The patent is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

“We are delighted that the USPTO has granted this patent, building further strength in Cynata’s comprehensive patent portfolio”, said Dr Ross Macdonald, Cynata’s Chief Executive Officer. “Our proprietary Cymerus stem cell manufacturing technology enables the scalable manufacture of consistent, high-quality mesenchymal stem cell therapeutic products targeting a range of devastating diseases worldwide.”

The inventors named on the patent are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and shareholders of Cynata.

The patent has an expiration date of 1 February 2028. [Read more…]

Positive Data from Cynata MSCs in Second Preclinical Asthma Study

By Leave a Comment

  • Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthma
  • Cymerus MSCs caused significantly greater reduction of airway hyperresponsiveness compared to corticosteroid treatment
  • Data suggest Cymerus MSCs can be administered alone or in combination with corticosteroids to treat the airway hyperresponsiveness associated with asthma
  • Completion of this study will further advance the path towards clinical trials

Cynata TherapeuticsMELBOURNE, Australia, Aug. 23, 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce further highly promising data supporting the efficacy of its proprietary Cymerus™ mesenchymal stem cells (MSCs) in a second preclinical asthma study.

The study was conducted under the supervision of Associate Professor Samuel and Dr Simon Royce of the Monash Lung Biology Network,1 focusing on the effects of CymerusTM MSCs in combination with or in comparison to the corticosteroid dexamethasone, which is commonly used to treat exacerbations of asthma in human patients. The study used a well-established mouse model of chronic allergic airways disease that closely resembles asthma in humans. This part of the study focused on airway hyperresponsiveness (AHR), which is a key clinical manifestation of asthma. [Read more…]

Patient Treatment Commences in Cynata’s World First Clinical Trial (CYP-001)

By 1 Comment

  • First patient with steroid resistant acute graft-versus-host disease (GvHD) treated in Cynata’s phase 1 clinical study of its mesenchymal stem cell (MSC) product, CYP-001
  • World first clinical trial using a MSC therapeutic product derived from an induced pluripotent stem cell sourced from a single blood donation from one donor
  • Transition into active clinical trials cements Cynata’s world leading position in the development and commercialisation of second generation stem cell products
  • Partnership with Fujifilm for the commercialisation of CYP-001; trial commencement accelerates this target

[Read more…]

BioInformant's World-Class Clients